{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "NEIL UNMACK", "person": [{"rank": 1, "role": "reported", "firstname": "Neil", "organization": "", "lastname": "UNMACK"}]}, "abstract": null, "type_of_material": "News", "word_count": "367", "lead_paragraph": "With the stake in Acerta, the British drug company\u2019s acquisitions this quarter total more than $7 billion. The deal-making reflects pipeline challenges and price pressure.", "pub_date": "2015-12-18T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "The Logic in AstraZeneca\u2019s Buying Spree", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "With the stake in Acerta, the British drug company\u2019s acquisitions this quarter total more than $7 billion. The deal-making reflects pipeline challenges and price pressure.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/12/18/business/dealbook/the-logic-in-astrazenecas-buying-spree.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "AstraZeneca PLC", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Europe", "name": "glocations"}], "blog": [], "_id": "567304fd38f0d85bed90f336", "source": "The New York Times"}